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Management of Established Status Epilepticus
Phil E. Smith, M.D.
Status epilepticus is a medical emergency char-
acterized either by continued seizures or by a lack 
of full recovery between seizures. It is relatively 
common, with a reported annual incidence of 
between 10 and 41 cases per 100,000 population 
(the variation partly reflects differing diagnostic 
criteria) and a mortality of approximately 20%.1 
The previous definition of status epilepticus as 
epileptic activity persisting for more than 30 min-
utes has been superseded2 with the aim of limit-
ing the irreversible neurologic damage that has 
been shown in animal models.3 Clinicians have 
long been urged instead to intervene early in the 
disorder, typically when seizures have persisted 
beyond 5 minutes.4 Adherence to standard evi-
dence-based management protocols that include 
this approach has been shown to improve out-
comes of status epilepticus in adults and chil-
dren,5 whereas delaying such intervention can 
allow seizures to persist and to become refrac-
tory, with risk of neurologic harm and death, 
particularly from generalized tonic–clonic status 
epilepticus.
Management protocols divide the medical ther-
apy for status epilepticus into three main stages. 
The first-line treatment for early status epilepti-
cus, often administered before the patient reach-
es the hospital, is a benzodiazepine6 — usually 
intravenous lorazepam or buccal midazolam. 
However, up to a third of cases are resistant to 
benzodiazepines. The second-line medication if 
status epilepticus becomes established is any one 
of the available intravenous preparations: fospheny-
toin (a precursor drug to phenytoin), levetirace-
tam, or sodium valproate given by infusion, 
usually in the hospital. Observational and retro-
spective data have suggested that valproate7 or 
levetiracetam8 has an advantage in efficacy, but 
there is insufficient evidence for the preference 
of one over another. In the absence of high-
quality data, the choice of drug depends on this 
ambiguous evidence regarding the efficacy and 
side-effect profiles, on the availability and cost 
of the drugs, and on regulatory approval.
Third-line treatment for refractory status epi-
lepticus, which is usually managed in an inten-
sive care unit, is not supported by high-quality 
evidence to guide the choice of one of three 
anesthetic agents: midazolam, propofol, or thio-
pental. It is unclear whether earlier intervention 
with anesthetics in status epilepticus could im-
prove outcomes at this stage, and we need fur-
ther studies to address this issue. A fourth stage 
of “super-refractory” status epilepticus — ongo-
ing seizures despite general anesthesia — has 
practically no meaningful evidence to support 
various desperate pharmacologic, immunologic, 
dietary, and surgical measures that have been 
tried on an individual basis.
The Established Status Epilepticus Treatment 
Trial (ESETT), described in this issue of the Jour-
nal,9 has assessed the relative efficacies and side-
effect profiles of the intravenous medications 
used as second-line therapy for status epilepti-
cus. The trial essentially showed that intravenous 
levetiracetam, fosphenytoin, and valproate each 
led to approximately 50% of patients having sei-
zure cessation at 1 hour, with similar percent-
ages of patients in the three treatment groups 
having adverse events. There was a trend toward 
a shorter time to seizure termination favoring 
valproate — 7.0 minutes, as compared with 10.5 
minutes for levetiracetam and 11.7 minutes for 
fosphenytoin — but these times could be ana-
lyzed only in the small subgroup of 39 patients 
(10%) for whom audio recordings had enabled 
accurate timing. It has been a commendable 
achievement to deliver a multicenter, randomized, 
double-blind trial of a potentially lifesaving intra-
venous medication to 384 patients within high-
pressure emergency department settings, includ-
ing explaining concepts of clinical equipoise, 
randomization, and consent to distressed care-
givers and relatives of an unconscious, convuls-
ing patient. Even the diagnosis of status epilep-
ticus itself is challenging, since this is still made 
mostly on clinical grounds and is sometimes in-
correct: 10% of the patients enrolled into ESETT 
were subsequently found to have dissociative 
(psychogenic, nonepileptic) seizures. However, 
the pragmatic decision not to require electroen-
cephalographic (EEG) monitoring for inclusion 
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in the trial reflects the limited availability of this 
technology and of its expert interpretation. We 
need further studies to determine the benefits of 
more widespread application of EEG technology 
for the diagnosis and monitoring of status epi-
lepticus.
The ESETT results may consolidate the drug 
management protocols for established (benzodi-
azepine-resistant) status epilepticus. Having three 
equally effective second-line intravenous medi-
cations means that the clinician may choose a 
drug that takes into account individual situa-
tions that may be modified by factors such as 
the presumed underlying cause of status epilep-
ticus; coexisting conditions, including allergy, 
liver and renal disease, hypotension, propensity 
to cardiac arrhythmia, and alcohol and drug 
dependence; the currently prescribed antiepilep-
tic treatment; the cost of the medication; and 
governmental agency drug approval.
The ESETT trialists have provided a service to 
adults and children with status epilepticus and 
to the teams managing their conditions. Provid-
ing evidence underpinning such an important 
treatment decision has the potential to save lives 
and brain tissue. But the practical challenge for 
the management of status epilepticus remains the 
same as in the past: ensuring that clinicians are 
familiar with, and follow, a treatment protocol.
Disclosure forms provided by the author are available with the 
full text of this editorial at NEJM.org.
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